A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT07619118
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07619118 -
2026-526258-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT07619118. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-10 (actual); primary completion 2027-05-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
- Condition
- Hypercholesterolaemia
- Intervention (Combination product)
- laroprovstat/rosuvastatin 1
- Intervention (Combination product)
- laroprovstat/rosuvastatin 2
- Intervention (Combination product)
- laroprovstat/rosuvastatin 3
- Intervention (Combination product)
- laroprovstat/rosuvastatin 4
- Intervention (Drug)
- Placebo to match laroprovstat/rosuvastatin 1,2,3
- Intervention (Drug)
- Placebo to match laroprovstat/rosuvastatin 4
- Intervention (Drug)
- Rosuvastatin 1
- Intervention (Drug)
- Rosuvastatin 2
- Intervention (Drug)
- Rosuvastatin 3
- Intervention (Drug)
- Rosuvastatin 4
- Intervention (Drug)
- Placebo to match Rosuvastatin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07619118- Content hash
5bd76dbd84c4ad7996c0ff4d87a59ba1c3184c6c6a8ccd2e799cb167053b048a